TP53 and prostate cancer: Similarly, under the administration of SC66, PAR polymer accumulation was happened in HepG2, a hepatocellular carcinoma cell line with wild type p53, but not occurred in DU145, a prostatic cancer cell line with mutated p53 (Fig. 6d).